報價延遲最少15分鐘:2025/09/04 04:01 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.88
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.59/-1.87
|
|
企業價值
2.77B
|
| 資產負債 |
|
每股賬面淨值
6.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
45.56M
|
|
每股收益
0.13
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 04:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
